You are viewing the site in preview mode

Skip to main content

Advertisement

Table 3 Selected published results of SRS (2000–2015) for the treatment of ATCH-secreting pituitary adenomas

From: Target delineation and optimal radiosurgical dose for pituitary tumors

Authors Patients Type dose Follow-up Tumor Biochemical Late toxicity (%)
of SRS (Gy) (months) control (%) remission (%) visual hypopituitarism
Izawa et al., 2000 [85] 12 GK 23.8a 26.4 100 17 NA 0
Sheehan et al., 2000 [113] 43 GK 20a 44 100 63 2 16
Hoybye et al., 2001 [114] 18 GK >25a 17 years 100 83 0 66
Devin et al., 2004 [115] 35 LINAC 14.7 35 91 49 0 40
Voges et al., 2006 [66] 17 LINAC 16.4 58.7 82.4 52.9 1.4 12.3
Castinetti et al., 2007 [116] 40 GK 29.5a 54.7 100 42.5 2.5 15
Jagannathan et al., 2007 [117] 90 GK 25a 45 96 54 5.5 22
Petit et al., 2007 [92] 33 Protons 20 62 94 52 0 52
Pollock et al., 2008 [118] 8 GK 18a 54 100 87 0 36
Tinnel et al., 2008 [119] 12 GK 25a 37 83.3 50 0 50
Wan et al., 2009 [98] 68 GK 23a 67.3 89.7 27.9 2.9 1.7
Kobayashi et al., 2009 [120] 30 GK 28.7a 64.1 100 35 NA NA
Hayashi et al., 2010 [70] 13 GK 25.2a 36 97 38 15.4 0
Sicignano et al., 2012 [37] 15 GK 23.8a 60 97.7 64 NA 12.3
Wein et al., 2012 [120] 17 LINAC 18 23 94.1 58.8 0 11.8
Zeiler et al., 2013 [105] 8 GK 24.7a 35 100 50 3.9 13.2
Grant et al., 2013 [121] 15 GK 35a 40.2 100 73 3.2 32
Sheehan et al., 2013 [122] 96 GK 22a 48 98 70 5 36
Wattson et al., 2014 [109] 74 Protons 20 47 98.6 67at 5 years 0 62 at 5 years
Wilson et al., 2014 [123] 36 LINAC 20 66 97 25 0 13.9
Marek et al., 2015 [35] 26 GK 29a 78 91.9 80.7 0 11.5
  1. SRS stereotactic radiosurgery, GK Gamma Knife, LINAC Linear Accelerator, CK CyberKnife, NA not assessed\
  2. amarginal dose